Vanda Pharmaceuticals (VNDA) Tops Q4 EPS by 4c; Guides Lower
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Price: $4.48 -1.75%
Revenue Growth %: +77,502.5%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Revenue Growth %: +77,502.5%
Financial Fact:
Research and development: 7.29M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of $0.12, $0.04 better than the analyst estimate of $0.08. Revenue for the quarter came in at $68 million versus the consensus estimate of $70.04 million.
GUIDANCE:
Vanda Pharmaceuticals sees FY2022 revenue of $240-280 million, versus the consensus of $313.62 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Arca Biopharma (ABIO) Reports Q1 Loss of $0.14
- Seacoast Banking Corporation of Florida (SBCF) Tops Q1 EPS by 2c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
